Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.64 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.56 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | MLYCD | O95822 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9546986 | 0.92 | MMP13 (0.84) | MMP13MAPK14HDAC6MLYCDCNR1 | |
| SCHEMBL4009230 | 0.91 | MMP13 (0.61) | MMP13MAPK14HSPB1CYP2C9MAPK11 | |
| SCHEMBL11248353 | 0.89 | MMP13 (0.63) | MMP13MAPK14CACNA1HHDAC6MLYCD | |
| SCHEMBL12093537 | 0.88 | MMP13 (0.61) | MMP13MAPK14CACNA1HHDAC6KCNH2 | |
| SCHEMBL4014284 | 0.87 | NAMPT (0.59) | MMP13MAPK14KCNH2CACNA1IPOLB | |
| SCHEMBL4013351 | 0.86 | MAPK14 (0.62) | MMP13MAPK14HSPB1CYP2C9MAPK11 | |
| SCHEMBL4009675 | 0.84 | SMN1; SMN2 (0.61) | MMP13MAPK14HDAC6LMNAPOLB | |
| SCHEMBL4492779 | 0.84 | MAPK14 (0.57) | MMP13MAPK14HSPB1CYP2C9MAPK11 | |
| SCHEMBL17888454 | 0.83 | SMYD3 (0.58) | MMP13MAPK14CACNA1H | |
| SCHEMBL15317662 | 0.83 | MAPK14 (0.57) | MMP13MAPK14HDAC6MLYCDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032142-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-11 | — | — | EP | claimed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | claimed |
| US-20160333011-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160024089-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| EP-1757582-B1 | ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-30 | — | — | EP | disclosed |
| US-20140378449-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-8889673-B2 | Triazolopyridine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8759387-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-06-24 | — | — | US | disclosed |
| US-8759387-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-06-24 | — | — | US | disclosed |
| US-8703721-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8703721-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20100249049-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MIYAZAKI HIROSHI | 2010-09-30 | — | — | US | disclosed |
| US-20100249049-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MIYAZAKI HIROSHI | 2010-09-30 | — | — | US | disclosed |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | GENENTECH, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| WO-2007042298-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378449-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | MMP13 3234/4885MAPK14 275/4885HSPB1 4207/4885 |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | JAK2, JAK1, JAK3 | MMP13 3234/4885MAPK14 275/4885HSPB1 4207/4885 |
| US-20160024089-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | MMP13 3234/4885MAPK14 275/4885HSPB1 4207/4885 |
| US-20160333011-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | MMP13 4163/4885MAPK14 270/4885HSPB1 4069/4885 |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | CASR, CNR1, CNR2 | MMP13 4849/4885MAPK14 2607/4885HSPB1 4221/4885 |
| US-20100249049-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | CASR, CNR1, CNR2 | MMP13 4849/4885MAPK14 2607/4885HSPB1 4221/4885 |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | CCNI, MKI67, CCNA1 | MMP13 2138/4885MAPK14 1745/4885HSPB1 2608/4885 |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | MMP13 3234/4885MAPK14 275/4885HSPB1 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.